December 18, 2014

Dr. Reddy’s Laboratories announced Tuesday that it has launched Valganciclovir Tablets USP 450 mg, a therapeutic equivalent generic version of the antiviral Valcyte (Valganciclovir) tablets, in the U.S. market.

December 16, 2014

Dr. Reddy's Labs announced the launch of valganciclovir tablets USP in 450-mg strength. 

 

November 24, 2014

Dr. Reddy's Labs on Monday announced the launch of docetaxel injection USP in 20-mg and 80-mg dosage strengths. The drug is the generic version of Taxotere.

 

November 20, 2014

Dr. Reddy’s Labs announced Thursday that it has launched a bioequivalent generic version of Allegra-D 12 Hour Allergy and Congestion, in the U.S. market.

November 11, 2014

Dr. Reddy's Labs received approval from the Food and Drug Administration for a generic version of Roche Holding's antiviral medication Valcyte, according to a Reuters report

October 30, 2014

Dr. Reddy's Labs on Tuesday announced the launch of sirolimus tablets in 1-mg and 2-mg dosage strengths.

September 24, 2014

Dr. Reddy's Labs on Wednesday announced the launch of levalbuterol inhalation solution, USP in 0.31-mg, 0.63-mg and 1.25-mg unit-dose vials.

July 31, 2014

Dr. Reddy's Labs announced financial results for the quarter ended June 30, which includes consolidated revenues of Rs.35.2 billion, representing year-on-year growth of 24%.

July 23, 2014

Generics supplier Camber Pharmaceuticals added two new executives to its team this week, bringing on Kirk Hessels as marketing director and Amanda Rebnicky as its sales operations director.

June 27, 2014

Dr. Reddy's Labs on Friday announced the launch of duloxetine delayed-release capsules USP in 20 mg, 30 mg and 60 mg dosage strengths.

June 25, 2014

Dr. Reddy's Labs on Wednesday announced that it has launched paricalcitol capsules in 1-mcg, 2-mcg and 4-mcg dosage strengths.

May 14, 2014

Dr. Reddy's Labs has named Satish Reddy as chairman of the board. Reddy previously held the position of vice-chairman, managing director and COO. GV Prasad will continue to serve as CEO and provide leadership to the company in an executive capacity.

May 14, 2014

Dr. Reddy’s Laboratories on Tuesday posted $2.2 billion in annual sales for the fiscal year ended March 31, representing growth of 14%.

April 23, 2014

Dr. Reddy's Labs on Wednesday announced the launch of fenofibrate capsules, USP in 43-mg and 130-mg strengths. The drug is the generic version of Antara (fenofibrate) capsules.

April 16, 2014

Dr. Reddy's Labs announced the launch of eszopiclone tablets (C-IV) in 1-mg, 2-mg and 3-mg form. The drug is the generic version of Lunesta (eszopiclone) tablets.

March 28, 2014

Dr. Reddy's Labs announced that it has launched amlodipine besylate and atorvastatin calcium tablets, a generic version of Caduet.

March 5, 2014

Dr. Reddy's Labs announced the launch of moxifloxacin hydrochloride tablets — the generic version of Avelox tablets — in 400-mg form.

February 26, 2014

Dr. Reddy's Labs announced that it has launched Sumatriptan Injection USP, Autoinjector System 6-mg/0.5-mL, a generic version of Imitrex STATdose Pen (sumatriptan succinate) 6-mg/0.5-mL.

February 18, 2014

From 2012 to 2017, global spending on medicines will increase from $205 billion to $235 billion, according to IMS Health. By 2017, 36% of the spend will be on generics, a number that is 9% more than the percentage in 2013.

December 17, 2013

Forty blockbuster drugs will use patent exclusivity in the United States between this year and 2020, according to a new study.

December 11, 2013

The Food and Drug Administration has approved the first generic versions of a drug used to treat depression and other conditions, the agency said.

November 8, 2013

The Food and Drug Administration has approved six generic versions of a drug used to treat gastroesophageal reflux disease, or GERD, the agency said Friday.

November 1, 2013

Indian drug maker Dr. Reddy's Labs had sales of $536 million in second quarter 2014 and profits of $110 million, the company said.

September 17, 2013

The Food and Drug Administration has approved an injected drug for the bone marrow disorder myelodysplastic syndrome made by Dr. Reddy's Labs, the company said Tuesday.